EUVIMEDEUVIMED entdecken
Crossref

LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the LumiThera Valeda Light Delivery System.

David W. Boyer, Hu, Allen, David J. Warrow, Samantha Xavier, Gonzalez, Victor, Eleonora Maries Lad, Richard B. Rosen, Diana V. Do, Todd E. Schneiderman, Hu und 10 weitere

Open Access CRIS of the University of Bern · 01.03.2024

DOI: 10.48350/189127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Access CRIS of the University of Bern, erschienen am 01.03.2024. Verfasst von David W. Boyer und 21 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The LIGHTSITE III study evaluated multiwavelength photobiomodulation (PBM) therapy in nonexudative (dry) AMD using the LumiThera Valeda® Light Delivery System. METHODS LIGHTSITE III is a randomized, controlled trial to assess the safety and effectiveness of PBM in dry AMD. Subjects were treated with multiwavelength PBM (590, 660 and 850 nm) or Sham treatment delivered 9 treatments over 3-5 weeks every four months over 24 months. Subjects were assessed for efficacy and safety outcomes. Data from the 13-month analysis are presented in this report. RESULTS A total of 100 subjects (148 eyes) with dry AMD were randomized. LIGHTSITE III met the primary efficacy BCVA endpoint with a significant difference between PBM (n = 91 eyes) and Sham (n = 54 eyes) groups (Between group difference: 2.4 letters (SE 1.15), CI: -4.7 - -0.1, p = 0.02)(PBM alone: 5.4 letters (SE 0.96), CI: 3.5 - 7.3, p < 0.0001; Sham alone: 3.0 letters (SE 1.13), CI: 0.7 - 5.2, p < 0.0001). The PBM group showed a significant decrease in new onset GA (p = 0.024, Fisher exact test, odds ratio 9.4). A favorable safety profile was observed. CONCLUSIONS LIGHTSITE III provides a prospective, randomized controlled trial showing improved clinical and anatomical outcomes in intermediate dry AMD following PBM.

Schlagwörter

low-level laser therapydry age-related macular degenerationbest-corrected visual acuitygeographic atrophytreatment safety

Zitieren

APA

Boyer, D. W., Hu, Allen, Warrow, D. J., Xavier, S., Gonzalez, Victor, Lad, E. M., Rosen, R. B., Do, D. V., Schneiderman, T. E., Hu, Allen, Munk, R, M., Jaffe, G. J., Tedford, S. E., Croissant, C. L., Walker, …, & Tedford, C. E. (2024). LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the LumiThera Valeda Light Delivery System. Open Access CRIS of the University of Bern. https://doi.org/10.48350/189127

Vancouver

Boyer DW, Hu, Allen, Warrow DJ, Xavier S, Gonzalez, et al. LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the LumiThera Valeda Light Delivery System. Open Access CRIS of the University of Bern. 2024. doi:10.48350/189127

BibTeX
@article{Boyer2024,
  author = {Boyer, David W. and Hu and Allen and Warrow, David J. and Xavier, Samantha and Gonzalez and Victor and Lad, Eleonora Maries and Rosen, Richard B. and Do, Diana V. and Schneiderman, Todd E. and Hu and Allen and Munk and R, Marion and Jaffe, G. J. and Tedford, Stephanie E. and Croissant, Cindy L. and Walker and Michael and Rückert, René and Tedford, Clark E.},
  title = {LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the LumiThera Valeda Light Delivery System},
  journal = {Open Access CRIS of the University of Bern},
  year = {2024},
  doi = {10.48350/189127}
}
Kostenlos starten →